Cytek Biosciences, Inc. (CTKB) Misses Q2 EPS by 8c ; Offers Guidance

Cytek Biosciences, Inc. (NASDAQ: CTKB) reported Q2 EPS of ($0.08), $0.08 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $46.6 million versus the consensus estimate of $49.53 million.

GUIDANCE:

Cytek Biosciences, Inc. sees FY2024 revenue of $203-210 million, versus the consensus of $208.8 million.

For earnings history and earnings-related data on Cytek Biosciences, Inc. (CTKB) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings